Why Ocugen Stock Is Crushing It Today Over 50 Finance January 4, 2021 What happened Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. The huge gain came after the company’s partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin.
Full Answer
Why did ocugen stock crash 19% lower on Friday?
Mar 04, 2022 · Shares of Ocugen ( OCGN -7.07% ) were crashing 19.2% lower as of 11:23 a.m. ET on Friday. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't ...
Is ocugen stock finally showing signs of weakness?
Jan 04, 2021 · 10 stocks we like better than Ocugen, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley ...
Should technical traders consider buying ocugen (ocgn) stock?
Mar 04, 2022 · What happened. Shares of Ocugen (NASDAQ: OCGN) were crashing 19.2% lower as of 11:23 a.m. ET on Friday. The steep decline came after the company announced that the U.S. Food and Drug ...
Does ocugen have the same profit share structure as America?
Sep 09, 2021 · Shares of Ocugen (NASDAQ:OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. The huge gain came after the company’s partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin.
Why is Ocugen stock dropping?
The decline is a continuation of the sell-off that began last week after Ocugen announced the Food and Drug Administration (FDA) rejected Emergency Use Authorization (EUA) for the pediatric use of COVID-19 vaccine Covaxin.Mar 8, 2022
Is Ocugen stock expected to rise?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +158.78% increase from the last price of 2.71.
Why is Ocugen stock up today?
What happened. Shares of Ocugen ( OCGN -7.07% ) had skyrocketed by 19.1% as of 11:15 a.m. ET on Tuesday. The huge gain came after the company announced that the Food and Drug Administration (FDA) had lifted the clinical hold on its investigational new drug (IND) application for COVID-19 vaccine Covaxin.Feb 22, 2022
Why is OCGN down?
Ocugen's OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin.Apr 13, 2022
Is Ocugen a good stock to buy?
Ocugen is a dangerous investment, especially given it is unprofitable, it's burning through money, and investors have been wary of growth stocks of late. Unless you're prepared for the risk, you're better off avoiding Ocugen.Feb 25, 2022
Is Ocugen a buy or sell?
Ocugen has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Investors didn't get what they wanted in the biotech's Q1 update
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Ocugen ( NASDAQ:OCGN) were tanking by 12.7% as of 11:16 a.m. EDT on Friday after falling as much as 20.6% earlier in the day. The big decline came after the company provided its first-quarter update before the market opened today.
So what
Ocugen didn't generate any revenue in the first quarter. The drugmaker posted a net loss of nearly $7.1 million, or $0.04 per share. Only two analysts surveyed by Refinitiv cover the stock. One expected revenue of $156.2 million and earnings of $1.01 per share, while the other analyst projected no revenue and a loss of $0.02 per share.
Now what
It's obvious that the big catalyst the biotech stock needs is for the FDA to indicate that it's open to an EUA filing for Covaxin based on Bharat's clinical studies in India. Expect Ocugen's shares to remain highly volatile until there's more clarity from the agency.
What is the difference between EUA and FDA?
One major difference between an EUA and full FDA approval is speed; in an emergency like the coronavirus pandemic, the regulator can quickly issue the former to a vaccine or drug given sufficient evidence of efficacy.
Is Ocugen a BLA?
Ocugen is following a recommendation from the FDA, which in feedback to Covaxin data urged the biotech to file for a biologics license application (BLA) instead of the EUA. The regulator also requested additional data and information on the vaccine candidate. Image source: Getty Images.
